Sugi Predict

Sugi Predict / Compounds / SCHEMBL1735965

SCHEMBL1735965

SCHEMBL1735965

BrCc1cccc2c1[nH]c1ccccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KIF11 P52732 5/20 0.53
▸ ALDH1A1 P00352 2/20 0.48
▸ HSD17B10 Q99714 2/20 0.48
▸ GPR3 P46089 1/20 0.48
▸ GABRP O00591 2/20 0.47
▸ GABRD O14764 2/20 0.47
▸ GABRA1 P14867 2/20 0.47
▸ GABRB1 P18505 2/20 0.47
▸ GABRG2 P18507 2/20 0.47
▸ GABRB3 P28472 2/20 0.47
▸ GABRA5 P31644 2/20 0.47
▸ GABRA3 P34903 2/20 0.47
▸ GABRA2 P47869 2/20 0.47
▸ GABRB2 P47870 2/20 0.47
▸ GABRA4 P48169 2/20 0.47
▸ GABRE P78334 2/20 0.47
▸ GABRA6 Q16445 2/20 0.47
▸ GABRG1 Q8N1C3 2/20 0.47
▸ GABRG3 Q99928 2/20 0.47
▸ GABRQ Q9UN88 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9331165 0.85 KIF11 (0.50) KIF11ALDH1A1HSD17B10GPR3GABRP
SCHEMBL11141346 0.84 KIF11 (0.57) KIF11ALDH1A1HSD17B10GPR3GABRP
SCHEMBL9935634 0.82 KIF11 (0.55) KIF11ALDH1A1HSD17B10GPR3GABRP
SCHEMBL3935135 0.81 KIF11 (0.46) KIF11ALDH1A1HSD17B10GPR3GABRP
SCHEMBL31433120 0.81 KIF11 (0.46) KIF11ALDH1A1HSD17B10GPR3GABRP
SCHEMBL157116 0.81 KIF11 (0.58) KIF11ALDH1A1HSD17B10GPR3GABRP
SCHEMBL291326 0.81 KIF11 (0.53) KIF11ALDH1A1HSD17B10GPR3GABRP
SCHEMBL21808458 0.81 KIF11 (0.53) KIF11ALDH1A1HSD17B10GPR3GABRP
SCHEMBL9935631 0.81 KIF11 (0.53) KIF11ALDH1A1HSD17B10GPR3GABRP
SCHEMBL11577428 0.81 KIF11 (0.53) KIF11ALDH1A1HSD17B10GPR3GABRP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8598312-B2 Inhibitors of antigen presentation by MHC class II molecules PROVID PHARMACEUTICALS, INC. (US) 2013-12-03 — — US disclosed
US-20120252734-A1 INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES OLSON GARY LEE (US) 2012-10-04 — — US disclosed
US-8222215-B2 Methods for the use of inhibitors of antigen presentation by MHC class II molecules PROVID PHARMACEUTICALS, INC. (US) 2012-07-17 — — US disclosed
EP-1605963-B1 INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES AND METHODS OF USE THEREOF PROVID PHARMACEUTICALS INC (US) 2011-11-16 — — EP disclosed
US-20110217324-A1 INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES AND METHODS OF USE THEREOF PROVID PHARMACEUTICALS, INC. 2011-09-08 — — US disclosed
EP-2229399-A1 INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES AND METHODS OF USE THEREOF Provid Pharmaceuticals, Inc. (US) 2010-09-22 — — EP disclosed
WO-2009073168-A1 INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES AND METHODS OF USE THEREOF PROVID PHARMACEUTICALS, INC. (US) 2009-06-11 — — WO disclosed
US-20090111755-A1 METHODS FOR THE USE OF INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES PROVID PHARMACEUTICALS, INC. 2009-04-30 — — US disclosed
US-7439231-B2 Inhibitors of antigen presentation by MHC class II molecules and methods of use thereof PROVID PHARMACEUTICALS, INC. (US) 2008-10-21 — — US disclosed
EP-1605963-A4 INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES AND METHODS OF USE THEREOF PROVID PHARMACEUTICALS INC (US) 2007-02-14 — — EP disclosed
EP-1605963-A2 INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES AND METHODS OF USE THEREOF Provid Pharmaceuticals, Inc. (US) 2005-12-21 — — EP disclosed
WO-2004073625-A2 INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES AND METHODS OF USE THEREOF PROVID PHARMACEUTICALS, INC. (US) 2004-09-02 — — WO disclosed
US-20040162242-A1 Inhibitors of antigen presentation by MHC class II molecules and methods of use thereof NJEDA 2004-08-19 — — US disclosed
US-5902884-A REACTING CARBAZOLE OR ALKYL, ALKOXY, NITRO OR HALOGEN SUBSTITUED DERIVATIVE WITH AN ALKYL HALIDE IN AN INERT SOLVENT WITH AN INORGANIC BASE AND DI- OR TRI-, ALKYLAMINE CATALYST; NO AFTERTREATMENT REQUIRED TO REMOVE CATALYST CLARIANT GMBH (DE) 1999-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162242-A1 Inhibitors of antigen presentation by MHC class II molecules and methods of use thereof HLA-DRB1, CD74, MICA KIF11 4103/4885ALDH1A1 2097/4885HSD17B10 2555/4885
US-20110217324-A1 INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES AND METHODS OF USE THEREOF HLA-DRB1, CD74, MICA KIF11 4389/4885ALDH1A1 2379/4885HSD17B10 2818/4885
US-20090111755-A1 METHODS FOR THE USE OF INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES HLA-DRB1, CD74, MICA KIF11 4084/4885ALDH1A1 1863/4885HSD17B10 2314/4885
US-20120252734-A1 INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES HLA-DRB1, CD74, MICA KIF11 4059/4885ALDH1A1 2074/4885HSD17B10 2550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.